RBC Capital Sticks to Their Hold Rating for Amgen Inc (AMGN)

By Ryan Adsit

In a report issued on August 9, Kennen MacKay from RBC Capital maintained a Hold rating on Amgen Inc (AMGNResearch Report). The company’s shares closed on Friday at $196.25.

According to TipRanks.com, MacKay is a 5-star analyst with an average return of 11.3% and a 54.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Akebia Therapeutics, and Puma Biotechnology.

Amgen Inc has an analyst consensus of Strong Buy, with a price target consensus of $213.80, which is an 8.9% upside from current levels. In a report issued on July 30, J.P. Morgan also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $210.19 and a one-year low of $166.30. Currently, Amgen Inc has an average volume of 2.86M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.